8-K: Avenue Sells Baergic Bio to Axsome, Eyes $82M Milestones

Avenue Therapeutics divests its majority-owned subsidiary Baergic Bio to Axsome Therapeutics, securing an upfront payment and potential future milestone and royalty payments for its epilepsy drug candidate.

Summary

• Avenue Therapeutics, Inc. (Avenue) and its majority-owned subsidiary, Baergic Bio, Inc. (Baergic), entered into a stock purchase agreement with Axsome Therapeutics, Inc. (Axsome) on November 5, 2025.
• Axsome purchased 100% of the equity interests in Baergic, acquiring worldwide commercial, development, and manufacturing rights to BAER-101 (now referred to as AXS-17).
• Avenue and other former Baergic stockholders received an upfront payment of $0.3 million (less transaction fees).
• They are eligible to receive up to $2.5 million in development and regulatory milestone payments for the first indication of AXS-17, and $1.5 million for each subsequent indication.
• Additionally, up to $79 million in aggregate commercial sales milestone payments are possible.
• A tiered mid-to-high single-digit royalty on potential global net sales of AXS-17 will also be paid.
• Avenue expects to receive approximately 74% of all future payments and royalties under the agreement.
• BAER-101 (AXS-17) is a novel oral GABAA α2,3 subtype-selective receptor positive allosteric modulator (PAM) originally licensed from AstraZeneca AB, which Axsome intends to evaluate as a potential treatment for epilepsy.
• In clinical studies involving over 700 patients, BAER-101 demonstrated an attractive safety and tolerability profile, with anti-convulsant effects observed in preclinical seizure models.

Sentiment

Score: 6

Explanation: The transaction provides a significant potential future revenue stream and validates a key asset for Avenue Therapeutics, which is positive for a company facing 'going concern' issues. However, the upfront payment is minimal, and the bulk of the value is contingent on future success, introducing substantial uncertainty.

Positives

• The transaction provides Avenue with potential future revenue streams through milestone payments totaling up to $82 million and tiered mid-to-high single-digit royalties on global net sales.
• The acquisition by Axsome validates BAER-101 (AXS-17) as a potentially best-in-class targeted therapy for epilepsy, addressing a high unmet medical need.
• Leveraging Axsome's expertise is expected to accelerate the development of AXS-17 for the benefit of epilepsy patients.
• The deal provides a strategic pathway for the progression of a key asset, potentially mitigating some of Avenue's financial uncertainties.

Negatives

• The upfront payment of $0.3 million (less transaction fees) is relatively small compared to the potential future contingent payments.
• Future milestone and royalty payments are contingent on successful development, regulatory approval, and commercial sales, which are not guaranteed.
• Avenue still faces substantial doubt about its ability to continue as a going concern and expects to incur losses for the foreseeable future, despite this transaction.

Risks

• Avenue currently has no drug products for sale, and its success is dependent on product candidates receiving regulatory approval and being successfully commercialized.
• Serious adverse or unacceptable side effects could be identified during development, leading to abandonment or limitation of product candidates.
• Uncertainty exists regarding the timing and amounts expected from future milestone, royalty, or similar revenue streams, if any.
• Avenue needs substantial additional funding, which may not be available on acceptable terms or at all, potentially forcing delays, reductions, or elimination of product development programs.
• Reliance on third parties for several aspects of operations and clinical data obtained by third parties could prove inaccurate or unreliable.
• Regulatory approval for product candidates may not be received or could be significantly delayed, and approved products would remain subject to substantial regulatory scrutiny.
• The company is exposed to the effects of current and future healthcare laws and regulations, competition, and the potential for new, better therapeutic alternatives.
• Government or third-party payors may fail to provide adequate coverage and payment rates for product candidates.
• Risks related to the protection of intellectual property and the ability to maintain sufficient patent protection exist.
• Fortress Biotech, Inc. controls a majority of Avenue's voting power and has rights to receive significant share grants annually.

Future Outlook

Axsome Therapeutics intends to evaluate AXS-17 as a potential treatment for epilepsy, leveraging its expertise to accelerate the development of this therapy. Avenue Therapeutics expects to receive approximately 74% of all future contingent payments and royalties from the agreement.

Management Comments

• "This acquisition by Axsome will enable the efficient progression of this potentially best-in-class targeted therapy for epilepsy."
• "By leveraging Axsomes expertise, we hope that the development of the therapy can be accelerated for the benefit of patients suffering from epilepsy."
• "We believe the potential potency, tolerability and efficacy of BAER-101 is exciting, as it creates an opportunity to improve the treatment of seizures in a field where there remains high unmet need for novel therapies."
• "This partnership further validates our model of sourcing and developing high-impact therapies that address large unmet needs, while creating meaningful opportunities for long-term shareholder value."

Industry Context

This acquisition highlights the ongoing trend of larger pharmaceutical companies acquiring promising early-to-mid-stage assets from smaller biotech firms, particularly in therapeutic areas with high unmet needs like neurologic diseases. The deal structure, involving an upfront payment combined with significant contingent milestones and royalties, is a common model in biotech M&A, allowing the acquiring company to mitigate risk while providing the selling company with potential long-term value.

Comparison to Industry Standards

• The deal structure, including an upfront payment, development/regulatory milestones, sales milestones, and tiered royalties, is a standard and widely accepted model for asset dispositions and acquisitions in the biotechnology and pharmaceutical industry.
• The valuation, particularly the small upfront payment relative to the potential total value, suggests that BAER-101 (AXS-17) is still in a relatively early stage of its commercialization pathway, with significant development and regulatory hurdles remaining, which is typical for such transactions involving pre-commercial assets.
• The focus on epilepsy, a therapeutic area with persistent unmet needs for novel therapies, aligns with broader industry efforts to develop targeted treatments for neurological disorders.

Management Changes

Stakeholder Impact

• Shareholders: Potential for significant future value through milestone and royalty payments, offering a long-term upside despite a small upfront payment.
• Employees (Management): Key executives received equity awards tied to the transaction's success, aligning their interests with future performance.
• Customers/Patients: The acquisition by Axsome is expected to accelerate the development of AXS-17, potentially bringing a new treatment option for epilepsy patients sooner.

Next Steps

• Axsome Therapeutics will proceed with evaluating AXS-17 as a potential treatment for epilepsy.
• Avenue Therapeutics and other former Baergic stockholders will be eligible to receive future milestone and royalty payments as AXS-17 progresses through development, regulatory, and commercialization stages.

Key Dates

Recommendation

The disposition of Baergic Bio provides Avenue Therapeutics with a potential lifeline and future revenue streams, validating its asset development model. However, the upfront payment is minimal, and the substantial future payments are contingent on the successful development, regulatory approval, and commercialization of AXS-17, which carries inherent risks and uncertainties. Given the company's stated 'going concern' issues, the transaction offers a path forward but does not immediately resolve all financial challenges, warranting a 'hold' position as investors await further progress on the contingent payments.

Keywords

Avenue Therapeutics, Baergic Bio, Axsome Therapeutics, BAER-101, AXS-17, epilepsy, GABAA modulator, pharmaceutical, biotech, acquisition, milestone payments, royalties, neurologic diseases